Literature DB >> 6167554

A supertypic HLA-DR specificity (DR4+5) defined by murine monoclonal antibody.

J A Hansen, P J Martin, M Kamoun, B Nisperos, E D Thomas.   

Abstract

The hybridoma technique was used to produce a monoclonal antibody specific for a polymorphic determinant on human la antigens. BALB/c mice were immunized with a B-lymphoblastoid cell line derived from an HLA-DR3/DR4 positive donor. Hybridoma culture supernates were screened in two stages by means of the microcytotoxicity assay. Supernates were first tested against the la-positive immunizing cell line and against la-negative cells. Cultures identified as producing antibody cytoxic for the immunizing cell line but not for la-negative cells were subcultured and the supernates then tested against a selected panel of HLA-D homozygous cell lines (HCL). In this manner, it was possible to identify a microwell of hybrid cells producing an antibody that reacted with a polymorphic HLA-DR determinant. Cells from this culture, designated 17.15, were cloned twice by limiting dilution. Specificity was evaluated with a panel of 39 HCL and B cells from 70 normal donors. Antibody 17.15 recognized a supertypic DR "4 + 5" specificity, which was also present on DRw9 and some DR7 positive cells. These findings suggest that the cross-reactivity groups DR "4 + 5" (MB-3) and DR "4 + 7" (MT-3) defined by alloantisera may share a common supertypic specificity that is recognized by monoclonal antibody 17.15.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6167554     DOI: 10.1016/0198-8859(81)90057-4

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.211


  4 in total

1.  T lymphocyte clones detecting novel supertypic HLA class II allospecificities.

Authors:  N Flomenberg; R W Knowles; D Williams; K Horibe; K Rosenkrantz; B Dupont
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

2.  A diabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -DQ alleles.

Authors:  M J Sheehy; S J Scharf; J R Rowe; M H Neme de Gimenez; L M Meske; H A Erlich; B S Nepom
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

3.  Detection of HLA-DR associated PLT determinants by alloreactive lymphocyte clones.

Authors:  A Zeevi; K Annen; C Scheffel; R J Duquesnoy
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

4.  A monoclonal antibody recognizing HLA-DR2 on malignant and activated cells.

Authors:  S V Fuggle; J Kirkley; A Ting; P J Morris
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.